ABSTRACT: Juvenile overlap syndromes are rare and complex conditions characterized by the coexistence of clinical and immunological features of at least two distinct connective tissue diseases.

In patients with juvenile localized scleroderma, treatment response to mycophenolate mofetil was comparable to that of methotrexate, but was associated with improved tolerability. Mycophenolate ...

Localized Scleroderma (LoS), particularly aggressive subtypes such as Deep Morphea (morphea profunda), is a rare chronic autoimmune fibrosing disorder that can extend into the subcutaneous tissue, ...

Juvenile localized scleroderma (JLS) is a rare, potentially disabling inflammatory skin disease, and there are currently no US Food and Drug Administration approved therapies for this population.

A RETROSPECTIVE cohort study has found that mycophenolate mofetil (MMF) demonstrates similar clinical effectiveness to methotrexate (MTX) in the treatment of juvenile localised scleroderma (JLS), ...

Researchers conducted a retrospective cohort study of 114 patients (68% female; median age at onset, 8.3 years; 92% White) with juvenile localized scleroderma from the National Registry for Childhood ...

Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial ...

Enolen's fast track designation by the FDA aims to expedite its development for localized prostate cancer treatment, addressing unmet medical needs. The localized delivery technology targets ...

Scleroderma, also known as systemic sclerosis, is a group of rare diseases that involve the hardening and tightening of the skin. It also may cause problems in the blood vessels, internal organs and ...

Scleroderma is an autoimmune condition that causes the skin to become tight and hard. This can change facial appearance, such as the mouth becoming smaller, and affect internal organs. With ...